skin cancer. Other malignant neoplasms of skin Incl.: malignant neoplasm of: sebaceous glands sweat glands
Conditions
Interventions
Intervention 1: 80 mg oral Aspirin for the intervention group. Intervention 2: Placebo in the control group.
Treatment - Drugs
Placebo
80 mg oral Aspirin for the intervention group
Sponsors
Vice chancellor of research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Adult patients who use Aspirin for at least 3 months, aged 40-75 years and INR between 1 and 1.5 Exclusion criteria: Dementia, movement disorders, simultaneous participation in another trial, severe life threatening cardiovascular disease (NYHA class III or more, history of myocardial infarction), valvular heart disease, bleeding disorders, use of other antiplatelet drugs or anticoagulants, history of gastrointestinal bleeding.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding volume within and after surgery. Timepoint: during the operation and 24 hous afterwards. Method of measurement: weight of blood absorbed to the dressing gas. | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of thrombosis. Timepoint: during surgery and 24 hous afterwards. Method of measurement: Clinical evaluation.;Hemodynamic unstability requiring reoperation. Timepoint: up to 24 hours from surgery. Method of measurement: Clinical evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Arman Engheta
Tehran University of Medical Sciences, Razi Hospital.
Outcome results
None listed